The deal with Cambridge University Health Partners and the Milner Therapeutics Institute will focus on research and innovation and will also offer opportunities for career development.
Biotech incubator Flagship Pioneering has signed a deal with Britain’s Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to advance breakthrough scientific research and technologies.
The collaboration will focus on research and innovation and will enable Flagship Pioneering’s ecosystem of more than 40 companies to partner with CUHP and MTI to access breakthrough science and technologies, clinical translation and trial support, and data assets and biosamples.
It will also allow for career development opportunities with the group’s Flagship Fellowship programme.
“Our collaboration with CUHP and MTI blends breakthrough research, clinical trial support, access to data assets, and accelerated talent development,” said Junaid Bajwa, senior partner and UK head of Flagship Pioneering.
Flagship intends to work with Cambridge University Health Partners and the Milner Therapeutics Institute to access opportunities in other organisations in the Cambridge life sciences ecosystem.
Flagship Pioneering invents and builds bioplatform companies that transform human health or sustainability. Since its launch in 2000, the company said that it has originated and fostered more than 100 scientific ventures, resulting in more than £48 billion in aggregate value.
